Navigation Links
Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Date:5/7/2009

-- Management to host call and webcast today at 5:00 p.m. Eastern to discuss financial results and recent business highlights --

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced unaudited financial results for the three months ended March 31, 2009.

Three Months Ended March 31, 2009

As of March 31, 2009, Orexigen held $19.8 million in cash and cash equivalents and an additional $44.9 million in investment securities, available-for-sale.

For the three months ended March 31, 2009, Orexigen reported a net loss of $19.3 million, or $0.56 per share attributable to common stockholders, as compared to a net loss of $23.2 million, or $0.73 per share attributable to common stockholders, for the comparable period in 2008.

Total operating expenses for the three months ended March 31, 2009 were $19.1 million compared to $24.0 million for the comparable period in 2008. The decreased operating expenses were due primarily to a decrease of $5.9 million in research and development expenses in connection with the Company's Contrave(R) Phase 3 clinical trials, related proprietary product formulation work and consulting activities, partially offset by an increase in salaries and personnel related costs. In addition, general and administrative expenses increased approximately $46,000 due primarily to an increase in salaries and personnel related costs.

"This is a momentous time for Orexigen," said Michael Narachi, President and CEO. "We are collecting the last of our patient data for the Contrave Phase 3 development program. We believe that if the data is positive, Contrave should have the ability to address a tremendously underserved obesity market. W
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
2. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
3. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
4. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
8. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
9. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
10. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
11. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Endo International plc (NASDAQ: ... Silva , President and CEO, will present a corporate overview ... York City on Wednesday, May 20, 2015 at ... audio archive for the event will be available on the ... and then the link to the event. Participants should allow ...
(Date:5/6/2015)... Follow us on LinkedIn ... with diameter ranging between 2 to 10 nanometers, ... materials market. The unique electroluminescent, photoluminescent, photo-physical, and ... confinement effect render the nanoparticles versatile and flexible ... technological, and commercial applications. A host of value-added ...
(Date:5/6/2015)... Tenney, a Thermal Product Solutions company, ... and custom environmental test chambers and rooms ... design, robust construction, and superior performance, the Tenney line ... of your temperature, humidity, altitude, vibration, and vacuum-testing requirements. ... TPS Smart 1.0 Controller. The Smart 1.0 Controller is ...
(Date:5/6/2015)...   University of Maryland (UM) Ventures and ... of an exclusive option by Biomecite Diagnostics for the ... diagnostics to detect inflammatory bowel diseases (IBD), such as ... Florian Fricke and James White developed ... of Maryland School of Medicine,s Institute for Genome Sciences ...
Breaking Biology Technology:Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 2Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 3The TPS 3.5” Smart 1.0 Controller Raises the Tech Standard on Environmental Test Chambers 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3
... , , , WORCESTER, Mass., Aug. ... Robert Lanza, its Chief Scientific Officer, is featured on Deepak Chopra,s Wellness ... 12 pm - 1 pm ET; Replays 1 pm - 4 am ... Lanza,s research at ACTC and his new book "Biocentrism." SIRIUS XM ...
... Enterprise ... ... South Korea (PRWEB) August 13, 2009 -- Xybion Medical Systems, a world leader in ... the market, is pleased to announce that Korea Institute of Toxicology (KIT) is upgrading ...
... ANNAPOLIS, Md., Aug. 13 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today reported financial and operational results for ... , For the second quarter of 2009, PharmAthene ... same period of 2008. For the six months ended June ...
Cached Biology Technology:Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 3Korea Institute of Toxicology Implementing Xybion's Pristima™ 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 8
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/27/2015)...  For more than four decades, AUVSI,s Unmanned ... premier worldwide event for the unmanned land, sea, and ... for any local, national, or trade news organization interested ... and current applications of unmanned technologies. The conference will ... billion industry, and how it will soon impact the ...
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... shipping to pre-order customers the first week of May, ... the month of May. Gino ... significant milestone for the company as Wocket® enters the ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... It is estimated that 38 million people worldwide are ... are added each year. For scientists to design treatment ... essential to learn more about how the virus mutates ... by University of Victoria biomedical engineer Stephanie Willerth has ...
... lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates ... cancers, according to data presented at the 33rd Annual ... Full results were presented at the symposium during a ... CT. Reporters who cannot attend in person ...
... Today, the International Osteoporosis Foundation (IOF) and the World ... University of Sheffield, UK announced the launch of a FRAX ... freely accessible online calculator which has been developed by the ... risk of fragility fractures based on clinical risk factors, with ...
Cached Biology News:UVic biomedical engineer 'outsmarts' HIV 2Combination therapy reduced HER2-positive breast cancers 2WHO Fracture Risk Assessment Tool (FRAX) newly released for Singapore 2
Human PDGF R beta MAb (Clone # PR7212)...
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: